HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
Stefan Schreiber 1
Julian Panés 2
Marc Fellmann 3
Lauren Bartolome 4
Martina Goetsch 4
Abhishek Bhattacharjee 5
Joseph Wu 6
María Chaparro 7, 8, 9
Marla C. Dubinsky 10
1 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
2 Formerly of Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
3 Pfizer AG, Zürich, Switzerland
4 Pfizer Inc, New York, United States
5 Pfizer Healthcare India Pvt. Ltd, Chennai, India
6 Pfizer Inc, Groton, United States
7 Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS Princesa), Madrid, Spain
8 Universidad Autónoma de Madrid (UAM), Madrid, Spain
9 Centro de Investigacíon Biomédica en Red de Enfermedades Hepáticas y Digestivas
10 Icahn School of Medicine at Mount Sinai, New York, United States
Topic
IBD
Session
PP 05 IBD (Posters)
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]